Part 1: ABCDEF Bundle Overview & Pain Assessment and Management
The ABCDEF bundle framework for ICU liberation, comprehensive pain assessment tools (BPS, CPOT, NRS) with complete scoring tables, and evidence-based analgesic management including opioid dosing, non-opioid adjuncts, and multimodal protocols.
The ABCDEF Bundle: A Framework for ICU Liberation
The ABCDEF bundle is an evidence-based, interprofessional approach to managing the interrelated domains of pain, sedation, delirium, immobility, and sleep in critically ill patients. Each element is complementary, and maximal benefit is achieved when all components are implemented together with high fidelity.1 2
Bundle Components
| Letter | Domain | Core Intervention |
|---|---|---|
| A | Assess, Prevent, and Manage Pain | Routine pain assessment with validated tools; analgesia-first approach; multimodal strategies |
| B | Both Spontaneous Awakening Trials (SAT) and Spontaneous Breathing Trials (SBT) | Daily paired SAT + SBT for ventilated patients when safety criteria are met |
| C | Choice of Analgesia and Sedation | Light sedation targeting (RASS 0 to −2); preference for non-benzodiazepine agents; analgesia-based sedation |
| D | Delirium: Assess, Prevent, and Manage | Routine delirium screening (CAM-ICU or ICDSC); non-pharmacologic prevention; treat underlying causes |
| E | Early Mobility and Exercise | Progressive mobilization beginning within 24–48 hours of ICU admission when hemodynamically stable |
| F | Family Engagement and Empowerment | Active family participation in care; structured communication; family presence at rounds and during procedures when appropriate |
Evidence for the ABCDEF Bundle
A prospective cohort study of over 15,000 adults across 68 ICUs demonstrated dose-dependent benefits of ABCDEF bundle compliance.2 For each 10% increase in proportional bundle compliance:
- Delirium: 15% lower odds of delirium the next day (adjusted OR 0.85, 95% CI 0.83–0.87)
- Coma: 15% lower odds of coma the next day (adjusted OR 0.85, 95% CI 0.82–0.88)
- Mechanical ventilation: 10% increase in the odds of being liberated from the ventilator within 3 days
- ICU discharge: 8% higher odds of ICU discharge alive within 7 days
- ICU readmission: 14% lower odds of ICU readmission
- Mortality: 32% lower likelihood of death during the 7-day analysis period for complete (100%) versus partial (≤ 20%) compliance
Implementation Principles
- Interprofessional coordination — the bundle requires collaboration among physicians, nurses, respiratory therapists, pharmacists, physical/occupational therapists, and families
- Routine, protocolized assessment — use validated tools at regular intervals (every 2–4 hours and before/after interventions)
- Documentation and feedback — bundle compliance should be tracked, reported, and used for continuous quality improvement
- Culture change — successful implementation requires institutional commitment, education, and dedicated champions in each discipline3
Section A: Pain Assessment and Management
Prevalence and Impact of Pain in the ICU
Pain is reported by more than 50% of critically ill patients at rest and up to 80% during common ICU procedures (turning, tracheal suctioning, wound care, arterial line insertion, chest tube removal).4 5 Unrecognized and untreated pain causes:
- Sympathetic activation (tachycardia, hypertension, increased myocardial oxygen demand)
- Splinting and hypoventilation, increasing atelectasis risk
- Agitation, self-removal of devices, and unplanned extubation
- Sleep disruption and delirium
- Immunosuppression and impaired wound healing
- Post-traumatic stress disorder (PTSD) after ICU discharge
Key Recommendations for Pain Management
| # | Recommendation | Strength |
|---|---|---|
| 1 | Routine pain assessment is recommended for all ICU patients, performed at regular intervals and documented | Strong recommendation |
| 2 | For patients able to self-report, the Numeric Rating Scale (NRS, 0–10) is the preferred pain assessment tool | Strong recommendation |
| 3 | For patients unable to self-report, behavioral pain scales — the Behavioral Pain Scale (BPS) or the Critical-Care Pain Observation Tool (CPOT) — are recommended | Strong recommendation |
| 4 | Vital signs alone should NOT be used to assess pain, though they may serve as a cue to initiate further assessment | Strong recommendation |
| 5 | An analgesia-first sedation approach is recommended, treating pain before administering sedative agents | Conditional recommendation |
| 6 | Multimodal analgesia (combining opioids with non-opioid adjuncts) is recommended to reduce total opioid requirements | Conditional recommendation |
| 7 | Pre-emptive analgesia should be administered before known painful procedures | Conditional recommendation |
Pain Assessment Tools
Numeric Rating Scale (NRS)
The NRS is the gold-standard self-report pain assessment tool for patients who can communicate. The patient rates pain intensity on a scale from 0 (no pain) to 10 (worst possible pain).4
| NRS Score | Pain Severity | Suggested Response |
|---|---|---|
| 0 | No pain | No intervention required |
| 1–3 | Mild pain | Non-pharmacologic interventions; consider non-opioid analgesics |
| 4–6 | Moderate pain | Pharmacologic intervention indicated; reassess within 30–60 minutes |
| 7–10 | Severe pain | Urgent pharmacologic intervention; reassess within 15–30 minutes |
When to use the NRS: The patient must be alert (RASS ≥ −1), oriented, and able to understand and respond to the question. If unable to verbalize, the patient may point to a number on a visual scale.
Behavioral Pain Scale (BPS)
The BPS is a validated tool for assessing pain in sedated, mechanically ventilated patients who cannot self-report. It evaluates three behavioral domains. Total score ranges from 3 (no pain) to 12 (maximum pain). A score ≥ 5 indicates clinically significant pain requiring intervention.4 6
BPS — Complete Scoring Table
| Domain | Description | Score |
|---|---|---|
| Facial Expression | ||
| Relaxed | 1 | |
| Partially tightened (e.g., brow lowering) | 2 | |
| Fully tightened (e.g., eyelid closing) | 3 | |
| Grimacing (e.g., brow lowering, eyelid tightening, nose wrinkling, lip raise, mouth opening) | 4 | |
| Upper Limb Movements | ||
| No movement | 1 | |
| Partially bent | 2 | |
| Fully bent with finger flexion | 3 | |
| Permanently retracted (pulling on tube or lines) | 4 | |
| Compliance with Mechanical Ventilation | ||
| Tolerating movement | 1 | |
| Coughing but tolerating ventilation for most of the time | 2 | |
| Fighting ventilator | 3 | |
| Unable to control ventilation (requiring manual ventilation) | 4 |
| BPS Total Score | Interpretation | Action |
|---|---|---|
| 3 | No pain behaviors observed | Continue monitoring every 2–4 hours |
| 4 | Possible pain | Reassess in 15 minutes; consider non-pharmacologic measures |
| 5–6 | Clinically significant pain | Administer analgesic; reassess in 30 minutes |
| 7–9 | Moderate-to-severe pain | Administer or escalate analgesic; reassess in 15–30 minutes |
| 10–12 | Severe pain | Urgent analgesic administration; consider bolus opioid; reassess in 15 minutes |
BPS for Non-Intubated Patients (BPS-NI): A modified version replaces the ventilator compliance domain with vocalization assessment:
| Vocalization (BPS-NI) | Score |
|---|---|
| No vocalization | 1 |
| Moaning (low-pitched, sustained sound) | 2 |
| Crying out (high-pitched sound, sustained or intermittent) | 3 |
| Screaming or verbal complaint of pain | 4 |
Critical-Care Pain Observation Tool (CPOT)
The CPOT evaluates four behavioral and one physiologic domain. Total score ranges from 0 (no pain) to 8 (maximum pain). A score ≥ 3 indicates clinically significant pain requiring intervention.4 7
CPOT — Complete Scoring Table
| Domain | Description | Score |
|---|---|---|
| Facial Expression | ||
| Relaxed, neutral — no muscular tension observed | 0 | |
| Tense — furrowing of brow, lowering of eyebrows, tightening of orbicularis oculi | 1 | |
| Grimacing — all of the above plus eyelids tightly closed, mouth opened, biting endotracheal tube | 2 | |
| Body Movements | ||
| Absence of movements or normal position — does not move at all (does not necessarily mean absence of pain) or normal position | 0 | |
| Protection — slow, cautious movements; touching or rubbing the pain site; seeking attention through movements | 1 | |
| Restlessness/agitation — pulling tube, attempting to sit up, moving limbs/thrashing, does not follow commands, striking at staff, trying to climb out of bed | 2 | |
| Compliance with Ventilator (Intubated) OR Vocalization (Non-Intubated) | ||
| Intubated: | ||
| Tolerating ventilator or movement — alarms not activated, easy ventilation | 0 | |
| Coughing but tolerating — alarms may be activated but stop spontaneously | 1 | |
| Fighting ventilator — asynchrony, blocking ventilation, alarms frequently activated | 2 | |
| Non-Intubated: | ||
| Talking in normal tone or no sound | 0 | |
| Sighing, moaning | 1 | |
| Crying out, sobbing | 2 | |
| Muscle Tension (evaluated by passive flexion and extension of the upper extremity) | ||
| Relaxed — no resistance to passive movements | 0 | |
| Tense, rigid — resistance to passive movements | 1 | |
| Very tense or rigid — strong resistance to passive movements or inability to complete them | 2 |
| CPOT Total Score | Interpretation | Action |
|---|---|---|
| 0 | No pain behaviors observed | Continue routine monitoring every 2–4 hours |
| 1–2 | Possible mild pain | Reassess in 15 minutes; consider non-pharmacologic measures |
| 3–4 | Clinically significant pain | Administer analgesic; reassess within 30 minutes |
| 5–6 | Moderate-to-severe pain | Administer or escalate analgesic; reassess within 15–30 minutes |
| 7–8 | Severe pain | Urgent analgesic administration; reassess within 15 minutes |
Choosing Between BPS and CPOT
| Feature | BPS | CPOT |
|---|---|---|
| Score range | 3–12 | 0–8 |
| Minimum score interpretation | 3 = no pain behaviors | 0 = no pain behaviors |
| Clinically significant pain threshold | ≥ 5 | ≥ 3 |
| Domains assessed | 3 (facial, limb movement, ventilator) | 4 (facial, body movement, ventilator/vocalization, muscle tension) |
| Can be used in non-intubated patients | Yes (BPS-NI variant) | Yes (vocalization replaces ventilator domain) |
| Validated populations | Medical, surgical, trauma ICU; post-operative | Medical, surgical, trauma ICU; post-operative; brain-injured |
| Sensitivity to pain interventions | Good | Good |
| Interrater reliability (kappa) | 0.67–0.83 | 0.52–0.88 |
Recommendation: Either BPS or CPOT may be used. The CPOT has a broader evidence base, includes muscle tension assessment, and has been validated in brain-injured patients. An institution should choose one tool and use it consistently.4
Pain Assessment Protocol
- Assess pain at least every 2 hours in all ICU patients and document
- Assess before and 15–30 minutes after any analgesic intervention
- Assess before, during, and after known painful procedures
- Use self-report (NRS) whenever possible — it is the most reliable measure
- Use BPS or CPOT for patients who cannot self-report
- Never rely on vital signs alone — tachycardia and hypertension have poor sensitivity and specificity for pain
- Consider proxy report (family members who know the patient’s typical pain behaviors) as a supplemental source
- Document and trend scores to evaluate treatment effectiveness
Pharmacologic Pain Management
Analgesia-First Approach
The 2018 guidelines recommend an analgesia-first (also called “analgosedation”) approach: treat pain before reaching for sedative agents. Many patients who appear agitated are actually in pain; treating the pain resolves the agitation without additional sedation. This approach is associated with:4 8
- Reduced total sedative use
- Shorter duration of mechanical ventilation
- Shorter ICU length of stay
- Lower incidence of delirium
Opioid Analgesics
Opioids remain the cornerstone of ICU pain management for moderate-to-severe pain, particularly pain associated with mechanical ventilation, surgical wounds, and invasive procedures. Intravenous administration is preferred for predictable pharmacokinetics.4 9
IV Opioid Dosing — Complete Reference Table
| Agent | IV Bolus Dose | Onset | Peak | Duration | Continuous Infusion | Key Considerations |
|---|---|---|---|---|---|---|
| Fentanyl | 25–100 mcg q 0.5–1 h | 1–2 min | 3–5 min | 0.5–1 h | 25–200 mcg/h (0.7–10 mcg/kg/h) | No active metabolites; preferred in renal/hepatic impairment; lipophilic — accumulates with prolonged use; chest wall rigidity at high doses (> 5 mcg/kg rapid bolus); no histamine release |
| Hydromorphone | 0.2–1 mg q 1–2 h | 5 min | 10–20 min | 2–4 h | 0.5–3 mg/h (7–15 mcg/kg/h) | 5–7× potency of morphine; minor active metabolite (hydromorphone-3-glucuronide — neuroexcitatory, accumulates in renal failure); less histamine release than morphine |
| Morphine | 2–5 mg q 1–2 h | 5–10 min | 15–30 min | 3–4 h | 2–30 mg/h (0.07–0.5 mg/kg/h) | Active metabolite (morphine-6-glucuronide) accumulates in renal failure — prolonged sedation/respiratory depression; causes histamine release — avoid in hemodynamically unstable patients and bronchospasm; oldest, most studied agent |
| Remifentanil | Not applicable (given only as infusion) | 1–3 min | 3–5 min | 3–10 min | 0.5–15 mcg/kg/h (starting 1.5 mcg/kg/h) | Ultra-short acting; metabolized by nonspecific plasma and tissue esterases — organ-independent elimination; ideal for neurologic assessments requiring rapid wake-up; no accumulation; may cause acute opioid tolerance and hyperalgesia with prolonged use; abrupt discontinuation causes rapid withdrawal |
| Methadone | 5–10 mg q 8–12 h (loading) | 10–20 min | 60–120 min | 4–8 h (initial); 24–36 h (steady state) | Not typically used as infusion | Long, variable half-life (15–60 h); NMDA receptor antagonist properties — useful for neuropathic pain and opioid tolerance; QTc prolongation risk — monitor ECG; useful for opioid rotation in tolerant patients |
Opioid Selection Algorithm
1. Is the patient hemodynamically unstable or in renal failure?
→ YES: Use fentanyl (no histamine release, no active metabolites in renal failure)
→ NO: Proceed to step 2
2. Are frequent neurologic assessments needed (e.g., TBI, post-neurosurgery)?
→ YES: Use remifentanil (ultra-short offset) or fentanyl (short offset)
→ NO: Proceed to step 3
3. Is the patient on prolonged opioid infusion with escalating requirements?
→ YES: Consider opioid rotation; add non-opioid adjuncts; consider methadone
→ NO: Proceed to step 4
4. Standard ICU patient requiring intermittent or continuous analgesia:
→ Fentanyl or hydromorphone preferred
→ Morphine acceptable if no renal impairment and hemodynamically stable
Opioid Equianalgesic Conversion Table (IV)
| Agent | IV Dose Equivalent to Morphine 10 mg IV |
|---|---|
| Fentanyl | 100 mcg |
| Hydromorphone | 1.5 mg |
| Morphine | 10 mg |
| Remifentanil | Not applicable (ultra-short acting; not converted) |
| Methadone | Conversion is complex and non-linear — consult pharmacy |
Non-Opioid Analgesic Adjuncts
Multimodal analgesia — the combination of opioids with non-opioid agents targeting different pain pathways — reduces opioid consumption, opioid-related side effects, and may improve pain control. The following agents are recommended as adjuncts:4 9 10
IV Acetaminophen (Paracetamol)
| Parameter | Details |
|---|---|
| Mechanism | Centrally acting; inhibits COX-3, serotonergic pathways, cannabinoid pathways |
| Dose | 1 g IV q 6 h (max 4 g/day); reduce to 500 mg q 6 h (max 2 g/day) if weight < 50 kg or hepatic impairment |
| Onset / Duration | 5–10 min / 4–6 h |
| Evidence | Reduces opioid consumption by 20–30% in post-operative and medical ICU patients |
| Precautions | Contraindicated in severe hepatic impairment (ALT > 10× ULN); dose reduction if CrCl < 30 mL/min in some protocols; monitor LFTs |
Ketorolac (NSAID)
| Parameter | Details |
|---|---|
| Mechanism | Non-selective COX inhibitor; potent analgesic and anti-inflammatory |
| Dose | 15–30 mg IV q 6 h; max duration 5 days; use 15 mg if age ≥ 65, weight < 50 kg, or renal impairment |
| Onset / Duration | 10–30 min / 4–6 h |
| Evidence | Reduces opioid requirements by 25–45% in surgical ICU populations |
| Precautions | GI bleeding risk; renal impairment (avoid if CrCl < 30 mL/min); platelet dysfunction; cardiovascular risk with prolonged use; avoid in hypovolemia; avoid concurrent with other NSAIDs or corticosteroids; hold in active hemorrhage |
Low-Dose Ketamine
| Parameter | Details |
|---|---|
| Mechanism | NMDA receptor antagonist; provides analgesia, anti-hyperalgesia, and anti-inflammatory effects at sub-anesthetic doses |
| Analgesic dose (sub-dissociative) | Bolus: 0.1–0.35 mg/kg IV; Infusion: 0.05–0.4 mg/kg/h (1–5 mcg/kg/min) |
| Onset / Duration | 30 seconds / 5–15 min (bolus); sustained during infusion |
| Evidence | Reduces opioid consumption; may reduce opioid-induced hyperalgesia; useful in patients with chronic pain, opioid tolerance, or neuropathic pain; may reduce delirium incidence (emerging evidence) |
| Precautions | Psychomimetic effects (vivid dreams, hallucinations) — generally minimal at analgesic doses; increases secretions; avoid in uncontrolled intracranial hypertension; historically cautioned in ICP concerns but recent evidence suggests safety when ventilation is controlled; increases heart rate and blood pressure — advantageous in hemodynamically unstable patients |
Gabapentin / Pregabalin
| Parameter | Gabapentin | Pregabalin |
|---|---|---|
| Mechanism | Binds alpha-2-delta subunit of voltage-gated calcium channels; modulates nociceptive signaling | Same mechanism |
| Dose | 100–300 mg PO/NG q 8 h; titrate to 1,200 mg TID (max 3,600 mg/day) | 50–75 mg PO/NG q 12 h; titrate to 150–300 mg BID (max 600 mg/day) |
| Indication in ICU | Neuropathic pain; opioid-sparing; may reduce post-surgical pain | Same indications; more predictable absorption |
| Evidence | Conditional recommendation as adjunct to reduce opioid use in surgical ICU patients | Same; may reduce delirium in cardiac surgery patients |
| Precautions | Renal dose adjustment required; sedation (additive with other CNS depressants); dizziness; requires enteral access | Same; lower dose needed than gabapentin for equivalent effect |
Renal dose adjustments for gabapentin:
| CrCl (mL/min) | Maximum Daily Dose |
|---|---|
| ≥ 60 | 3,600 mg (divided TID) |
| 30–59 | 1,400 mg (divided BID) |
| 15–29 | 700 mg (once daily) |
| < 15 or HD | 300 mg (once daily; supplement 200–300 mg after each hemodialysis session) |
Lidocaine IV Infusion
| Parameter | Details |
|---|---|
| Mechanism | Sodium channel blockade; systemic anti-inflammatory, anti-hyperalgesic |
| Dose | Loading: 1–1.5 mg/kg IV over 10 min; Infusion: 1–2 mg/kg/h (max 3 mg/kg/h) |
| Monitoring | Continuous cardiac monitoring; serum lidocaine levels q 12–24 h if infusion > 24 h; therapeutic analgesic range 1.5–5 mcg/mL; toxic > 5 mcg/mL |
| Evidence | Reduces opioid consumption in post-operative patients; may reduce ileus duration; emerging evidence in burns and trauma |
| Precautions | Cardiac conduction abnormalities (AV block, bradycardia); seizures at toxic levels; hepatic metabolism (reduce dose in liver failure); avoid with other class I antiarrhythmics; monitor for perioral numbness, tinnitus, metallic taste (early toxicity signs) |
Regional Anesthesia and Nerve Blocks in the ICU
Regional anesthesia provides targeted analgesia with minimal systemic effects and is increasingly used in critically ill patients.10 11
| Technique | Primary Indications | Considerations |
|---|---|---|
| Thoracic epidural | Rib fractures (≥ 3), thoracotomy, upper abdominal surgery | Improved pulmonary mechanics, reduced opioid use; contraindicated with coagulopathy or hemodynamic instability requiring vasopressors; risk of epidural hematoma/abscess |
| Paravertebral block | Rib fractures, thoracotomy | Alternative to epidural; unilateral; fewer hemodynamic effects; can be performed in anticoagulated patients (with caution) |
| Erector spinae plane (ESP) block | Rib fractures, thoracic surgery, abdominal surgery | Fascial plane block — lower risk profile; can place catheter for continuous infusion; evidence growing |
| Transversus abdominis plane (TAP) block | Abdominal surgery, laparotomy | Provides somatic analgesia to anterior abdominal wall; does not cover visceral pain |
| Femoral nerve / fascia iliaca block | Hip fracture, femur fracture | Excellent for lower extremity; reduces opioid requirements significantly |
| Serratus anterior plane block | Chest wall trauma, chest tubes, thoracotomy | Provides lateral chest wall analgesia |
| Scalp block | Craniotomy, TBI with external ventricular drain | Reduces systemic analgesic requirements |
Anticoagulation and neuraxial procedures — safety guidelines:
| Anticoagulant | Time to Hold Before Neuraxial Procedure | Resume After Procedure |
|---|---|---|
| Unfractionated heparin (SQ prophylactic) | 4–6 hours; check aPTT | 1 hour after |
| Unfractionated heparin (IV therapeutic) | 4–6 hours; aPTT must be normal | 1 hour after |
| Enoxaparin (prophylactic, 40 mg daily) | 12 hours | 4 hours after |
| Enoxaparin (therapeutic, 1 mg/kg BID) | 24 hours | 4 hours after |
| Warfarin | INR ≤ 1.4 | After catheter removal |
| Direct oral anticoagulants (rivaroxaban, apixaban) | 72 hours (or 3 half-lives) | 6 hours after |
| Clopidogrel | 7 days | After catheter removal |
| Aspirin (alone) | No contraindication | No restriction |
Multimodal Analgesia Protocol
The following protocol represents an evidence-based approach to multimodal, opioid-sparing analgesia in the ICU:4 9
Step 1 — Baseline for all patients (unless contraindicated):
- IV acetaminophen 1 g q 6 h (scheduled)
Step 2 — Add based on pain type and severity:
- Somatic/surgical pain: Add ketorolac 15–30 mg IV q 6 h (max 5 days) if no contraindication
- Neuropathic component: Add gabapentin 100–300 mg PO q 8 h (titrate) or pregabalin 50–75 mg PO q 12 h
- Opioid-tolerant/hyperalgesia: Add low-dose ketamine infusion 0.05–0.2 mg/kg/h
Step 3 — Opioid analgesia for breakthrough and moderate-to-severe pain:
- Fentanyl 25–50 mcg IV q 30 min PRN, or
- Hydromorphone 0.2–0.5 mg IV q 1–2 h PRN
- If persistent moderate-severe pain: initiate continuous infusion (fentanyl 25–100 mcg/h or hydromorphone 0.5–2 mg/h)
Step 4 — Consider regional anesthesia:
- Rib fractures: thoracic epidural, paravertebral, or ESP block
- Abdominal surgery: epidural or TAP block
- Extremity fractures: peripheral nerve block
Step 5 — Reassess and titrate:
- Reassess pain (BPS/CPOT/NRS) q 2 h and after each intervention
- Titrate to target: NRS ≤ 3, BPS < 5, CPOT < 3
- Taper opioid infusions by 10–25% every 6–12 h as pain improves
- Transition from IV to enteral analgesics when absorptive capacity returns
Procedural Pain Management
Common ICU procedures cause predictable, significant pain. Pre-emptive analgesia should be provided before procedures whenever possible.4 5
Pain Intensity of Common ICU Procedures
| Procedure | Average Pain Intensity (NRS 0–10) | Category |
|---|---|---|
| Turning/repositioning | 4.9 | Moderate |
| Tracheal suctioning | 4.6 | Moderate |
| Wound drain removal | 5.2 | Moderate-Severe |
| Chest tube removal | 5.5 | Moderate-Severe |
| Arterial line insertion | 3.8 | Mild-Moderate |
| Central venous catheter insertion | 3.5 | Mild-Moderate |
| Wound care/dressing change | 5.1 | Moderate-Severe |
| Physical therapy/mobilization | 4.1 | Moderate |
| Femoral catheter removal | 4.2 | Moderate |
| Bronchoscopy | 3.9 | Mild-Moderate |
Pre-Procedural Analgesia Protocol
| Procedure Pain Level | Recommended Pre-Treatment | Timing |
|---|---|---|
| Mild (NRS < 4 expected) | Acetaminophen 1 g IV; consider non-pharmacologic measures | 15–30 min before |
| Moderate (NRS 4–6 expected) | Fentanyl 25–50 mcg IV OR hydromorphone 0.2–0.5 mg IV | 5–10 min before |
| Severe (NRS ≥ 7 expected) | Fentanyl 50–100 mcg IV AND consider ketamine 0.1–0.35 mg/kg IV; local/regional anesthesia when feasible | 5–10 min before |
Non-Pharmacologic Pain Interventions
Non-pharmacologic methods should be used alongside, not instead of, pharmacologic analgesia:4
| Intervention | Evidence Level | Application |
|---|---|---|
| Repositioning and comfort measures | Moderate | Proper body alignment; offloading pressure areas; pillow support |
| Cold therapy (cryotherapy) | Moderate | Post-operative incisions; musculoskeletal pain; 15–20 min application |
| Music therapy | Moderate | Calming music via headphones during procedures and at rest; reduces anxiety and analgesic requirements |
| Relaxation / guided imagery | Low-Moderate | For alert patients; reduces anxiety component of pain |
| Massage | Low | May reduce pain and anxiety; limited evidence in ICU |
| Family presence | Low | Reduces anxiety and may reduce pain perception |
| Environmental modification | Low-Moderate | Noise reduction; light dimming; minimizing unnecessary stimulation |
References
Marra A, Ely EW, Pandharipande PP, Patel MB. “The ABCDEF Bundle in Critical Care.” Crit Care Clin. 2017;33(2):225-243. DOI: 10.1016/j.ccc.2016.12.005 ↩︎
Pun BT, Balas MC, Barnes-Daly MA, et al. “Caring for Critically Ill Patients with the ABCDEF Bundle: Results of the ICU Liberation Collaborative in Over 15,000 Adults.” Crit Care Med. 2019;47(1):3-14. DOI: 10.1097/CCM.0000000000003482 ↩︎ ↩︎
Barnes-Daly MA, Phillips G, Ely EW. “Improving Hospital Survival and Reducing Brain Dysfunction at Seven California Community Hospitals: Implementing PAD Guidelines Via the ABCDEF Bundle in 6,064 Patients.” Crit Care Med. 2017;45(2):171-178. DOI: 10.1097/CCM.0000000000002149 ↩︎
Devlin JW, Skrobik Y, Gélinas C, et al. “Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU.” Crit Care Med. 2018;46(9):e825-e873. DOI: 10.1097/CCM.0000000000003299 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Puntillo KA, Max A, Tiber R, et al. “Determinants of Procedural Pain Intensity in the Intensive Care Unit: The Europain Study.” Am J Respir Crit Care Med. 2014;189(1):39-47. DOI: 10.1164/rccm.201306-1174OC ↩︎ ↩︎
Payen JF, Bru O, Bosson JL, et al. “Assessing Pain in Critically Ill Sedated Patients by Using a Behavioral Pain Scale.” Crit Care Med. 2001;29(12):2258-2263. DOI: 10.1097/00003246-200112000-00004 ↩︎
Gélinas C, Fillion L, Puntillo KA, Viens C, Fortier M. “Validation of the Critical-Care Pain Observation Tool in Adult Patients.” Am J Crit Care. 2006;15(4):420-427. DOI: 10.4037/ajcc2006.15.4.420 ↩︎
Strøm T, Martinussen T, Toft P. “A Protocol of No Sedation for Critically Ill Patients Receiving Mechanical Ventilation: A Randomised Trial.” Lancet. 2010;375(9713):475-480. DOI: 10.1016/S0140-6736(09)62072-9 ↩︎
Barr J, Fraser GL, Puntillo K, et al. “Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit.” Crit Care Med. 2013;41(1):263-306. DOI: 10.1097/CCM.0b013e3182783b72 ↩︎ ↩︎ ↩︎
Chou R, Gordon DB, de Leon-Casasola OA, et al. “Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists.” J Pain. 2016;17(2):131-157. DOI: 10.1016/j.jpain.2015.12.008 ↩︎ ↩︎
Horlocker TT, Vandermeuelen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. “Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition).” Reg Anesth Pain Med. 2018;43(3):263-309. DOI: 10.1097/AAP.0000000000000763 ↩︎